The use of layered double hydroxides as DNA vaccine delivery vector for enhancement of anti-melanoma immune response

Biomaterials

Volumn 32, Issue 2, 2011, Pages 469-477

  Li, Ang ^a   Qin, Lili ^a   Wang, Wenrui ^a   Zhu, Rongrong ^a   Yu, Yongchun ^a   Liu, Hui ^b   Wang, Shilong ^a  

^a TONGJI UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

DNA vaccine; Layered double hydroxides; Melanoma; T help cell

Indexed keywords

ANTIBODY RESPONSE; AVERAGE DIAMETER; C57BL/6 MICE; DNA COMPLEX; DNA PLASMIDS; DNA VACCINE; GFP EXPRESSION; IMMUNE RESPONSE; IN-VIVO; LAYERED DOUBLE HYDROXIDES; MELANOMA; NAKED DNA; T HELP CELL; TRANSFECTION EFFICIENCY; TUMOR MODELS;

DERMATOLOGY; DNA; GENE TRANSFER; IMMUNIZATION; MICROBIOLOGY; NANOPARTICLES; ONCOLOGY; TUMORS;

VACCINES;

DNA; DNA VACCINE; HYDROXIDE; MELANOMA VACCINE; NAKED DNA; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DNA DRUG COMPLEX; DNA TRANSFECTION; DRUG DELIVERY SYSTEM; FEMALE; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNITY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; FEMALE; HYDROXIDES; MELANOMA; MICE; MICE, INBRED C57BL; NANOPARTICLES; T-LYMPHOCYTES; VACCINES, DNA;

MUS;

EID: 78449236912     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.08.107     Document Type: Article

References (38)

1. Pachuk C.J., McCallus D.E., Weiner D.B., Satishchandran C. DNA vaccines-challenges in delivery. Curr Opin Mol Ther 2000, 2:188-198.
2. Letvin N.L., Montefiori D.C., Yasutomi Y., Perry H.C., Davies M.E., Lekutis C., et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 1997, 94:9378-9383.
3. Calatota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E., et al. Cellular cytotoxic responses induced by DNA vaccination in HIV-1-infected patients. Lancet 1998, 351:1320-1325.
4. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282:476-480.
5. Boutorine A.S., Kostina E.V. Reversible covalent attachment of cholesterol to oligodeoxy-ribonucleotides for studies of the mechanisms of their penetration into eukaryotic cells. Biochim Clin 1993, 75:35-41.
6. Barry M.E., Pinto-Gonzalez D., Orson F.M., McKenzie G.J., Petry G.R., Barry M.A. Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection. Hum Gene Ther 1999, 10:2461-2480.
7. Nguyen D.N., Green J.J., Chan J.M., Langer R., Anderson D.G. Polymeric materials for gene delivery and DNA vaccination. Adv Mater 2008, 20:1-21.
8. Morille M., Passirani C., Vonarbourg A., Clavreul A., Benoit J.P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008, 29:3477-3496.
9. Mumper R.J., Ledebur H.C. Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization. Mol Biotechnol 2001, 19:79-95.
10. Singh M., Briones M., Ott G., O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A 2000, 97:811-816.
11. Illum L., Jabbal-Gill I., Hinchcliffe M., Ficsher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001, 51:81-96.
12. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-335.
13. Felgner J.H., Kumar R., Sridhar C.N., Wheeler C.J., Tsai Y.J., Border R., et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994, 269:2550-2561.
14. Gregoriadis G., McCormack B., Obrenovic M., Saffie R., Zadi B., Perrie Y. Vaccine entrapment in liposomes. Methods 1999, 19:156-162.
15. Xu Z.P., Nieber M., Porazik K., Walker T.L., Cooper H.M. Subcellular compartment targeting of layered double hydroxide nanoparticles. J Control Release 2008, 130:86-94.
16. Choy J.H., Jung J.S., Oh J.M., Park M. Layered double hydroxides as an efficient drug reservoir for folate derivatives. Biomaterials 2004, 25:3059-3064.
17. Li A., Qin L., Zhu D., Zhu R., Sun J., Wang S.L. Signalling pathways involved in the activation of dendritic cells by layered double hydroxide nanoparticles. Biomaterials 2010, 31:748-756.
18. Wu C.J., Huang H.W., Tao M.H. Induction of cross-protection against two wildtype Taiwanese isolates of Japanese encephalitis virus using Beijing-1 strain DNA vaccine. Vaccine 2003, 21:3938-3945.
19. Hanada T., Tanaka K., Matsumura Y. Induction of hyper Th1 cell-type immune responses by dendritic cells lacking the suppressor of cytokine signaling-1 gene. J Immunol 2005, 174:4325-4332.
20. Lecoeur H., Fevrier M., Garcia S., Rivière Y., Gougeon M.L. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 2001, 253:177-187.
21. 2O as a continuous function of nitrate anions. J Phys Chem B 2001, 105:1743-1749.
22. Tyner K.M., Schiffman S.R., Giannelis E.P. Nanobiohybrids as delivery vehicles for camptothecin. J Control Release 2004, 95:501-514.
23. Desigaux L., Belkacem M.B., Richard P., Cellier J., Léone P., Cario L., et al. Self-assembly and characterization of layered double hydroxide/DNA hybrids. Nano Lett 2006, 6:199-204.
24. Masarudin M.J., Yusoff K., Rahim R.A., Hussein M.Z. Successful transfer of plasmid DNA into in vitro cells transfected with an inorganic plasmid-Mg/Al-LDH nanobiocomposite material as a vector for gene expression. Nanotechnology 2009, 20:602-613.
25. Xu Z.P., Walker T.L., Liu K.L., Cooper H.M., Lu G.Q., Bartlett P.F. Layered double hydroxide nanoparticles as cellular delivery vectors supercoiled plasmid DNA. Int J Nanomedicine 2007, 2:163-174.
26. Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2003, 2:305-315.
27. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010, 28:445-489.
28. Hermann-Kleiter N., Baier G. NFAT pulls the strings during CD4+ T helper cell effector functions. Blood 2010, 115:2989-2997. [Review].
29. Huang H.N., Li T.L., Chan Y.L., Chen C.L., Wu C.J. Transdermal immunization with low-pressure-gene-gun mediated chitosan-based DNA vaccines against Japanese encephalitis virus. Biomaterials 2009, 30:6017-6025.
30. Garg S., Oran A., Wajchman J., Sasaki S., Maris C.H., Kapp J.A., et al. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol 2003, 4:907-912.
31. Raju R. Tracking the general: tagging skin-derived dendritic cells. Trends Biotechnol 2004, 22:58-59.
32. Diveu C., McGeachy M.J., Cua D.J. Cytokines that regulate autoimmunity. Curr Opin Immunol 2008, 20:663-668.
33. Kalinski P., Nakamura Y., Watchmaker P., Giermasz A., Muthuswamy R., Mailliard R.B. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res 2006, 36:137-146. [Review].
34. Zhang T., Herlyn D. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother 2009, 58:475-492. [Review].
35. Ahlers J.D., Belyakov I.M. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 2010, 115:1678-1689.
36. Krieg A.M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008, 27:161-167.
37. Arce S., Nawar H.F., Russell M.W., Connell T.D. Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells. Infect Immun 2005, 73:2718-2727.
38. Vuist W.M., van Buitenen F., Hekman A., Melief C.J. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies. Cancer Res 1990, 50:5767-5772.